Sartorius edges up after Q3 earnings beats

By Reuters News

** Shares in Sartorius SATG.DE rise 2.4% after the biopharma supplier reported better-than-expected Q3 revenue, adjusted EBITDA

** The German company posted quarterly revenue of €926 million ($1.04 billion), with adjusted EBITDA of €280 million, which both exceeded Vara consensus expectations of €899 million and €269 million respectively

** "Sartorius delivered a strong third quarter," Jefferies says

** The stock, which has gained a fifth in value since mid-September, tops Germany's midcap index .MDAXI

** Its French unit Stedim Biotech STDM.PA shares also rise about 2%, being the second-best performer

** Sartorius AG preferential shares are up 4.2%

($1 = 0.8896 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.